Overview
- Bronstein, Gewirtz & Grossman announced a federal securities class action has been filed against Erasca and certain officers alleging false or misleading statements about ERAS-0015.
- The complaint asserts Erasca’s preclinical data rested on improper comparisons to Revolution Medicines and that those comparisons exposed the company to patent and trade-secret claims.
- The suit seeks damages for investors who bought Erasca securities during a defined class period and the firm says investors have until August 10, 2026 to ask the court to be lead plaintiff.
- Bronstein, Gewirtz & Grossman is soliciting class members and will represent investors on a contingency-fee basis while noting the claims come from the firm’s complaint and remain unproven.
- No court rulings or settlements have been reported and Erasca has not provided a response in these releases; prior company disclosures cited by coverage include a RevMed challenge to Erasca’s IP and a reported patient death linked to ERAS-0015 that preceded a sharp share price drop.